OASIS-HIT

Design of a pharmacogenomic dose-finding study

Jan A. Staessen, Tatiana Kuznetsova, Rok Acceto, Antonella Bacchieri, Eva Brand, Michel Burnier, Hilde Celis, Lorena Citterio, Peter W. de Leeuw, Jan Filipovský, Albert Fournier, Kalina Kawecka-Jaszcz, Paolo Manunta, Yuri Nikitin, Eoin T. O'Brien, Josep Redón, Lutgarde Thijs, Patrizia Ferrari, Giovanni Valentini, Giuseppe Bianchi

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Experimental evidence and observations in humans strongly support an interactive role of mutated α-adducin, sodium (Na+) /potassium (K+)-adenosine triphosphatase (ATPase) activity and endogenous ouabain in Na+ homeostasis and the pathogenesis of hypertension. The Ouabain and Adducin for Specific Intervention on Sodium in HyperTension (OASIS-HT) trial is an early Phase II dose-finding study, which will be conducted across 39 European centers. Following a run-in period of 4 weeks without treatment, eligible patients will be randomize to one of five oral doses of rostafuroxin consisting of 0.05, 0.15, 0.5, 1.5, or 5.0 mg/day. Each dose will be compared to a placebo in a double-blind crossover experiment with balanced randomization. Treatment will be initiated with the active drug and continued with placebo or vice versa. Each double-blind period will last 5 weeks. The primary end point is the reduction in systolic blood pressure defined as the average of three clinic readings with the patient in the sitting position. Secondary end points include the reduction in diastolic blood pressure on clinic measurement, the decrease in the 24-h blood pressure, and the incidence of end points related to safety. Secondary objectives are to investigate the dependence of the blood pressure-lowering activity on the plasma concentration of endogenous ouabain and the genetic variation of the enzymes involved in the metabolism of this hormone, and the adducin cytoskeleton proteins. Eligible patients will have Grade I or II systolic hypertension without associated conditions and no more than two additional risk factors. In conclusion, OASIS-HT is a combination of five concurrent crossover studies, one for each dose of rostafuroxin to be studied. To our knowledge, OASIS-HT is the first Phase II dose-finding study in which a genetic hypothesis is driving primary and secondary end points.

Original languageEnglish
Pages (from-to)755-775
Number of pages21
JournalPharmacogenomics
Volume6
Issue number7
DOIs
Publication statusPublished - Oct 2005

Fingerprint

Pharmacogenetics
Ouabain
Blood Pressure
Hypertension
Sodium
Placebos
Random Allocation
Cytoskeleton
Posture
Cross-Over Studies
Adenosine Triphosphatases
poly(divinyl-co-N-vinylpyrrolidinone)
Reading
Potassium
Homeostasis
Cohort Studies
adducin
Hormones
Safety
Incidence

Keywords

  • Adducin
  • Dose-finding
  • Hypertension
  • Ouabain
  • Pharmacogenomic
  • Phase-II
  • Rostafuroxin
  • Sodium
  • Trial

ASJC Scopus subject areas

  • Pharmacology
  • Genetics(clinical)

Cite this

Staessen, J. A., Kuznetsova, T., Acceto, R., Bacchieri, A., Brand, E., Burnier, M., ... Bianchi, G. (2005). OASIS-HIT: Design of a pharmacogenomic dose-finding study. Pharmacogenomics, 6(7), 755-775. https://doi.org/10.2217/14622416.6.7.755

OASIS-HIT : Design of a pharmacogenomic dose-finding study. / Staessen, Jan A.; Kuznetsova, Tatiana; Acceto, Rok; Bacchieri, Antonella; Brand, Eva; Burnier, Michel; Celis, Hilde; Citterio, Lorena; de Leeuw, Peter W.; Filipovský, Jan; Fournier, Albert; Kawecka-Jaszcz, Kalina; Manunta, Paolo; Nikitin, Yuri; O'Brien, Eoin T.; Redón, Josep; Thijs, Lutgarde; Ferrari, Patrizia; Valentini, Giovanni; Bianchi, Giuseppe.

In: Pharmacogenomics, Vol. 6, No. 7, 10.2005, p. 755-775.

Research output: Contribution to journalArticle

Staessen, JA, Kuznetsova, T, Acceto, R, Bacchieri, A, Brand, E, Burnier, M, Celis, H, Citterio, L, de Leeuw, PW, Filipovský, J, Fournier, A, Kawecka-Jaszcz, K, Manunta, P, Nikitin, Y, O'Brien, ET, Redón, J, Thijs, L, Ferrari, P, Valentini, G & Bianchi, G 2005, 'OASIS-HIT: Design of a pharmacogenomic dose-finding study', Pharmacogenomics, vol. 6, no. 7, pp. 755-775. https://doi.org/10.2217/14622416.6.7.755
Staessen JA, Kuznetsova T, Acceto R, Bacchieri A, Brand E, Burnier M et al. OASIS-HIT: Design of a pharmacogenomic dose-finding study. Pharmacogenomics. 2005 Oct;6(7):755-775. https://doi.org/10.2217/14622416.6.7.755
Staessen, Jan A. ; Kuznetsova, Tatiana ; Acceto, Rok ; Bacchieri, Antonella ; Brand, Eva ; Burnier, Michel ; Celis, Hilde ; Citterio, Lorena ; de Leeuw, Peter W. ; Filipovský, Jan ; Fournier, Albert ; Kawecka-Jaszcz, Kalina ; Manunta, Paolo ; Nikitin, Yuri ; O'Brien, Eoin T. ; Redón, Josep ; Thijs, Lutgarde ; Ferrari, Patrizia ; Valentini, Giovanni ; Bianchi, Giuseppe. / OASIS-HIT : Design of a pharmacogenomic dose-finding study. In: Pharmacogenomics. 2005 ; Vol. 6, No. 7. pp. 755-775.
@article{a95a0765187147b68234c14c39ae0b12,
title = "OASIS-HIT: Design of a pharmacogenomic dose-finding study",
abstract = "Experimental evidence and observations in humans strongly support an interactive role of mutated α-adducin, sodium (Na+) /potassium (K+)-adenosine triphosphatase (ATPase) activity and endogenous ouabain in Na+ homeostasis and the pathogenesis of hypertension. The Ouabain and Adducin for Specific Intervention on Sodium in HyperTension (OASIS-HT) trial is an early Phase II dose-finding study, which will be conducted across 39 European centers. Following a run-in period of 4 weeks without treatment, eligible patients will be randomize to one of five oral doses of rostafuroxin consisting of 0.05, 0.15, 0.5, 1.5, or 5.0 mg/day. Each dose will be compared to a placebo in a double-blind crossover experiment with balanced randomization. Treatment will be initiated with the active drug and continued with placebo or vice versa. Each double-blind period will last 5 weeks. The primary end point is the reduction in systolic blood pressure defined as the average of three clinic readings with the patient in the sitting position. Secondary end points include the reduction in diastolic blood pressure on clinic measurement, the decrease in the 24-h blood pressure, and the incidence of end points related to safety. Secondary objectives are to investigate the dependence of the blood pressure-lowering activity on the plasma concentration of endogenous ouabain and the genetic variation of the enzymes involved in the metabolism of this hormone, and the adducin cytoskeleton proteins. Eligible patients will have Grade I or II systolic hypertension without associated conditions and no more than two additional risk factors. In conclusion, OASIS-HT is a combination of five concurrent crossover studies, one for each dose of rostafuroxin to be studied. To our knowledge, OASIS-HT is the first Phase II dose-finding study in which a genetic hypothesis is driving primary and secondary end points.",
keywords = "Adducin, Dose-finding, Hypertension, Ouabain, Pharmacogenomic, Phase-II, Rostafuroxin, Sodium, Trial",
author = "Staessen, {Jan A.} and Tatiana Kuznetsova and Rok Acceto and Antonella Bacchieri and Eva Brand and Michel Burnier and Hilde Celis and Lorena Citterio and {de Leeuw}, {Peter W.} and Jan Filipovsk{\'y} and Albert Fournier and Kalina Kawecka-Jaszcz and Paolo Manunta and Yuri Nikitin and O'Brien, {Eoin T.} and Josep Red{\'o}n and Lutgarde Thijs and Patrizia Ferrari and Giovanni Valentini and Giuseppe Bianchi",
year = "2005",
month = "10",
doi = "10.2217/14622416.6.7.755",
language = "English",
volume = "6",
pages = "755--775",
journal = "Pharmacogenomics",
issn = "1462-2416",
publisher = "Future Medicine Ltd.",
number = "7",

}

TY - JOUR

T1 - OASIS-HIT

T2 - Design of a pharmacogenomic dose-finding study

AU - Staessen, Jan A.

AU - Kuznetsova, Tatiana

AU - Acceto, Rok

AU - Bacchieri, Antonella

AU - Brand, Eva

AU - Burnier, Michel

AU - Celis, Hilde

AU - Citterio, Lorena

AU - de Leeuw, Peter W.

AU - Filipovský, Jan

AU - Fournier, Albert

AU - Kawecka-Jaszcz, Kalina

AU - Manunta, Paolo

AU - Nikitin, Yuri

AU - O'Brien, Eoin T.

AU - Redón, Josep

AU - Thijs, Lutgarde

AU - Ferrari, Patrizia

AU - Valentini, Giovanni

AU - Bianchi, Giuseppe

PY - 2005/10

Y1 - 2005/10

N2 - Experimental evidence and observations in humans strongly support an interactive role of mutated α-adducin, sodium (Na+) /potassium (K+)-adenosine triphosphatase (ATPase) activity and endogenous ouabain in Na+ homeostasis and the pathogenesis of hypertension. The Ouabain and Adducin for Specific Intervention on Sodium in HyperTension (OASIS-HT) trial is an early Phase II dose-finding study, which will be conducted across 39 European centers. Following a run-in period of 4 weeks without treatment, eligible patients will be randomize to one of five oral doses of rostafuroxin consisting of 0.05, 0.15, 0.5, 1.5, or 5.0 mg/day. Each dose will be compared to a placebo in a double-blind crossover experiment with balanced randomization. Treatment will be initiated with the active drug and continued with placebo or vice versa. Each double-blind period will last 5 weeks. The primary end point is the reduction in systolic blood pressure defined as the average of three clinic readings with the patient in the sitting position. Secondary end points include the reduction in diastolic blood pressure on clinic measurement, the decrease in the 24-h blood pressure, and the incidence of end points related to safety. Secondary objectives are to investigate the dependence of the blood pressure-lowering activity on the plasma concentration of endogenous ouabain and the genetic variation of the enzymes involved in the metabolism of this hormone, and the adducin cytoskeleton proteins. Eligible patients will have Grade I or II systolic hypertension without associated conditions and no more than two additional risk factors. In conclusion, OASIS-HT is a combination of five concurrent crossover studies, one for each dose of rostafuroxin to be studied. To our knowledge, OASIS-HT is the first Phase II dose-finding study in which a genetic hypothesis is driving primary and secondary end points.

AB - Experimental evidence and observations in humans strongly support an interactive role of mutated α-adducin, sodium (Na+) /potassium (K+)-adenosine triphosphatase (ATPase) activity and endogenous ouabain in Na+ homeostasis and the pathogenesis of hypertension. The Ouabain and Adducin for Specific Intervention on Sodium in HyperTension (OASIS-HT) trial is an early Phase II dose-finding study, which will be conducted across 39 European centers. Following a run-in period of 4 weeks without treatment, eligible patients will be randomize to one of five oral doses of rostafuroxin consisting of 0.05, 0.15, 0.5, 1.5, or 5.0 mg/day. Each dose will be compared to a placebo in a double-blind crossover experiment with balanced randomization. Treatment will be initiated with the active drug and continued with placebo or vice versa. Each double-blind period will last 5 weeks. The primary end point is the reduction in systolic blood pressure defined as the average of three clinic readings with the patient in the sitting position. Secondary end points include the reduction in diastolic blood pressure on clinic measurement, the decrease in the 24-h blood pressure, and the incidence of end points related to safety. Secondary objectives are to investigate the dependence of the blood pressure-lowering activity on the plasma concentration of endogenous ouabain and the genetic variation of the enzymes involved in the metabolism of this hormone, and the adducin cytoskeleton proteins. Eligible patients will have Grade I or II systolic hypertension without associated conditions and no more than two additional risk factors. In conclusion, OASIS-HT is a combination of five concurrent crossover studies, one for each dose of rostafuroxin to be studied. To our knowledge, OASIS-HT is the first Phase II dose-finding study in which a genetic hypothesis is driving primary and secondary end points.

KW - Adducin

KW - Dose-finding

KW - Hypertension

KW - Ouabain

KW - Pharmacogenomic

KW - Phase-II

KW - Rostafuroxin

KW - Sodium

KW - Trial

UR - http://www.scopus.com/inward/record.url?scp=26944459544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26944459544&partnerID=8YFLogxK

U2 - 10.2217/14622416.6.7.755

DO - 10.2217/14622416.6.7.755

M3 - Article

VL - 6

SP - 755

EP - 775

JO - Pharmacogenomics

JF - Pharmacogenomics

SN - 1462-2416

IS - 7

ER -